Platelet-rich Plasma Injection for Ulnar Neuropathy at Elbow

• Status: Recruiting
• Trial end date: 2022-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Ulnar neuropathy at elbow (UNE) is the second common peripheral entrapment neuropathy after carpal tunnel syndrome (CTS). Although many conservative managements of UNE were found, their effectiveness were often unsatisfied without existed guideline. Recently, the perineural injection of 5% dextrose wate (D5W) is a novel management for CTS but its effect for UNE is not obviously as CTS. Hence, it is very important to find another novel injectate for UNE.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yung-Tsan Wu

Criteria

Inclusion Criteria:

1. Age between 20-80 year-old.

2. Diagnosis as ulnar neuropathy at elbow at least one month

Exclusion Criteria:

1. Cancer

2. Coagulopathy

3. Pregnancy

3. Any active infection status 4. Polyneuropathy of upper extremity 5. Brachial plexopathy

6. Thrombocytopenia Previously undergone wrist surgery or steroid injection for ulnar neuropathy